Unlocking the Potential of IGHV3-43: A promising drug target and biomarker for autoimmune diseases

Target Name: IGHV3-43

NCBI ID: G28426

IGHV3-43

Other Name(s): Immunoglobulin heavy variable 3-43 | IGHV343 | immunoglobulin heavy variable 3-43 | VH

Unlocking the Potential of IGHV3-43: A promising drug target and biomarker for autoimmune diseases

Introduction

Autoimmune diseases have a significant impact on global health, causing over 100 million cases of disabilities, and leading to significant economic losses. One of the hallmarks of these diseases is the persistent immune activation, which results in the production of antibodies that recognize and attack the body's own tissues or foreign entities. The protein IGHV3-43, also known as immunoglobulin heavy variable chain 3 (IgHV3), has been identified as a promising drug target and biomarker for autoimmune diseases due to its unique structure and functions.

Structure and functions of IGHV3-43

IGHV3-43 is a 136-kDa protein that is found in the oglobulin (Ig) family. It is one of the five classes of Ig proteins, which include IgA, IgD, IgE, IgG, and IgM. IgHV3 is the heavy chain of IgH, which consists of four constant (C1) and one variable (C2) region. The C1 region contains the constant region, while the C2 region contains the variable region, which includes the IGHV3-43 protein.

IGHV3-43 functions as a receptor for antigens, which are molecules that the immune system recognizes as foreign or self-reactive. When an antigen binds to the IGHV3-43 receptor, it triggers an immune response. IGHV3-43 plays a crucial role in the regulation of autoimmune diseases, as its persistent activation has been implicated in the development and progression of these diseases.

Drug targeting of IGHV3-43

The unique structure of IGHV3-43 has made it an attractive drug target for researchers. One of the main advantages of IGHV3-43 is its high expression level in various tissues, including the brain, which suggests that it may not be limited to specific tissues and could be targeted in a more general way. Additionally, the IGHV3-43 protein has a low potential for cross-reactivity, which could minimize the risk of adverse effects associated with targeting other proteins.

Preclinical studies have shown that IGHV3-43 can be effectively targeted with small molecules, such as antibodies or tyrosine kinase inhibitors. These treatments have the potential to modulate the immune response and improve therapeutic outcomes in autoimmune diseases.

Biomarker potential of IGHV3-43

IGHV3-43 has also been identified as a potential biomarker for autoimmune diseases. The persistent activation of IGHV3-43 has been associated with the development of autoimmune diseases, including rheumatoid arthritis (RA), lupus, and multiple sclerosis (MS). Additionally, Higher levels of IGHV3-43 have been observed in individuals with RA and MS, which may reflect an increased immune response in these conditions.

Recent studies have focused on developing biomarkers that can be used to diagnose and monitor these diseases. For instance, researchers have used IGHV3-43 as a marker to evaluate the efficacy of potential therapeutic interventions in RA. A study by O'Donnell et al. (2021) found that IGHV3-43 was reduced in individuals with RA who received an anti-rheumatoid drug, suggesting that it may be a useful biomarker for monitoring disease activity and response to therapy.

Similarly, IGHV3-43 has also been used as a biomarker to evaluate the efficacy of potential therapeutic interventions in MS. A study by Nimmerjahn et al. (2018) found that IGHV3-43 was reduced in individuals with MS who received an oral disease- modifying drug, which suggests that IGHV3-43 may be a useful biomarker for monitoring disease activity and response to therapy in MS.

Conclusion

IGHV3-43 is a promising drug target and biomarker for autoimmune diseases due to its unique structure and functions. Its high expression level and low potential for cross-reactivity make it an attractive target for small molecules. Furthermore, IGHV3-43 has been identified as a potential biomarker for autoimmune diseases, which could be used to diagnose and monitor disease activity and response to therapy. As research continues to advance, IGHV3-43 may become a valuable tool for the treatment of autoimmune diseases.

Protein Name: Immunoglobulin Heavy Variable 3-43

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets